secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001628280-24-052579
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost
--------------------------------------------------------------------------------

- Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.
- Sangamo forfeits up to $220M in remaining milestones and all future royalties (14-20% of net sales).
- Sangamo receives exclusive license back to develop and commercialize SB-525; Pfizer gets low single digit royalties.
- Sangamo plans to seek a new partner to advance regulatory filings for giroctocogene fitelparvovec.
- Pfizer had paid $125M already ($70M upfront + $55M milestones); remaining program rights revert.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024052579/0001628280-24-052579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024052579/sgmo-20241222.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-052579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer